Lumida
/AKTS
⌘K
AKTS

AKTS

AKTS
$26.18USD↓-1.24%-0.33 today

MARKET CAP

1.5B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$26 – $27

52W RANGE

$0
$34

AI Summary

Stalk
Buy NowMedium

AKTS remains in a structural uptrend, trading above its key moving averages and consolidating near immediate support. The 200-day SMA confirms long-term bullish momentum, while the alignment and tight tracking of the 9/20/50 EMAs support further upward potential. In the medium term, the absence of a clear breakout pattern and proximity to near-term resistance warrants caution, though bullish bias remains intact. Short-term timing is favorable now, as price holds just above the 20 EMA and within the $24.80-$25.00 support zone with no evident exhaustion.

  • ↑Cash, cash equivalents, and marketable securities of $517.3M fund ops through 2029.
  • ↑Q2 2026 revenue rose 113% YoY to $3.4M, reflecting pipeline traction.
  • ↓Q2 net loss jumped to $24.1M from $18.1M year-ago, driven by R&D spend.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Aktis Oncology (NASDAQ: AKTS) is an emerging biotechnology company focused on developing innovative cancer therapies through its proprietary platforms, particularly targeting tumor-associated antigens such as B7-H3. Operating at the forefront of immunotherapy, Aktis is navigating through a competitive landscape where personalized medicine and targeted therapies are paramount, notably enhancing its potential amidst the rising demand for effective cancer treatments.

Bull says

  • ↑Cash, cash equivalents, and marketable securities of $517.3M fund ops through 2029.
  • ↑Q2 2026 revenue rose 113% YoY to $3.4M, reflecting pipeline traction.
  • ↑AKY-2519 trial data indicate effective tumor targeting and reduced off-target exposure.
  • ↑Analysts rate a Moderate Buy with price targets of $34.60–$37.00.
  • ↑High institutional ownership and low leverage suggest financial stability.
  • ↑Eli Lilly collaboration boosts revenue and enhances market credibility.

Bear says

  • ↓Q2 net loss jumped to $24.1M from $18.1M year-ago, driven by R&D spend.
  • ↓High operating expenses hinder path to profitability in coming quarters.
  • ↓Revenue concentration with key partners poses cash-flow risk if agreements lapse.
  • ↓Muted growth outlook and downward earnings revisions may cap upside.
  • ↓Elevated stock volatility could deter risk-averse investors.
  • ↓Weak profitability metrics and negative revision trends raise sustainability concerns.

Earnings Call · Q3 2023 · Mgmt. Guidance

Updated 08-23-2026neutral

Transcript signals

Bull points

  • Acoustus drove unit and top line growth once again to achieve another quarter of record revenue of $7.4 million, which was within the 20% to 40% growth range we guided to on our last call.
  • Our current backlog supports sequential revenue growth in a range of 10% to 20%.
  • We remain focused on driving revenue and unit growth across all our target end markets, with a particular emphasis on 5G mobile and infrastructure, Wi-Fi 6E and 7AP, IoT, and automotive applications.

Bear points

  • And finally, I would like to provide an update on our defense and other businesses. On a GAAP basis, operating loss was $17.3 million for the March quarter, mainly driven by revenue of $7.4 million, offset by labor costs of 11.3 million, depreciation and amortization of 3.1 million, and other operational costs totaling 10.3 million.
  • On a GAAP basis, operating loss was $17.3 million for the March quarter, mainly driven by revenue of $7.4 million, offset by labor costs of 11.3 million, depreciation and amortization of 3.1 million, and other operational costs totaling 10.3 million.
  • On a GAAP basis, operating loss was $17.3 million for the March quarter, mainly driven by revenue of $7.4 million, offset by labor costs of 11.3 million, depreciation and amortization of 3.1 million, and other operational costs totaling 10.3 million.
Read full transcript analysis ›